ER、PR和C-erbB-2在乳腺浸润性导管癌中的表达及其相关性

目的探讨ER、PR和C-erbB-2在乳腺浸润性导管癌中的表达及其相关性。方法收集84例乳腺浸润性导管癌石蜡标本,应用免疫组化"二步法"检测ER、PR和C-erbB-2在上述病变中的表达。结果 ER阳性57例,PR阳性42例,C-erbB-2阳性58例,ER、PR和C-erbB-2表达与乳腺癌患者年龄、肿瘤大小、淋巴结转移情况没有明显相关性。ER和PR的表达与C-erbB-2的表达没有明显相关性。ER、PR表达呈正相关。乳腺癌患者的年龄与淋巴结是否转移没有明显相关性。结论ER、PR和C-erbB-2的表达与临床各因素无明显相关性,联合检测ER、PR及C-erbB-2对临床上判断乳腺癌预后、指导治疗的意义不确定。

地黄饮子联合耳针对肾虚髓减型内分泌治疗期绝经后乳腺癌患者认知水平及激素水平、血脂、维生素D3水平的影响

目的:探究地黄饮子联合耳针对肾虚髓减型内分泌治疗期绝经后乳腺癌患者认知水平、临床症状及生化指标的影响。方法:100例接受内分泌治疗的绝经后乳腺癌患者,根据入院先后使用数字表法随机分为实验组和对照组,实验组患者50例,对照组患者50例。对照组患者接受常规乳腺癌内分泌、补钙治疗加耳针治疗,治疗组患者在对照组基础上服用地黄饮子煎剂,两组患者均连续治疗2个月后进行MMSE、MoCA、FSS量表评估,检测患者生化指标:游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、雌二醇(E2)、促黄体生成素(LH)、促卵泡生成素(FSH)、胆固醇(TC)、甘油三酯(TG)、维生素D3(1,25-(OH)2-VitD3)。结果:治疗组总有效率高于对照组;治疗后两组认知评分均较治疗前有所提高(P<0.05),而治疗后治疗组认知评分高于对照组(P<0.05);治疗后两组疲劳评分均较治疗前有所降低(P<0.05),而治疗后治疗组认知评分低于对照组(P<0.05);治疗后两组FT3、FT4、TSH、E2、LH、1,25-(OH)2-VitD3水平均较治疗前提高(P<0.05),而治疗后治疗组上述指标高于对照组(P<0.05);治疗后两组TC、TG、LH、FSH均较治疗前有所降低(P<0.05),而治疗后治疗组上述指标低于对照组(P<0.05)。结论:地黄饮子联合耳针可以有效地改善肾虚髓减型内分泌治疗期绝经后乳腺癌患者认知水平,其作用可能与相关激素水平、血脂及血清D3含量改变有关,且安全可靠,值得研究。

Chinese female breast cancer patients show a better overall survival than their male counterparts

Backgroud It is not clear if there is a difference in prognosis between male breast cancer （MBC） and female breast cancer （FBC） patients. The aim of this study was to compare the prognosis of MBC and FBC patients in China and the prognosis of MBC and their corresponding postmenopausal FBC patients.Methods Thirty-five MBC patients who were treated at the Sun Yat-sen University Cancer Center between 1969 and 2004 were enrolled in the study. Seventy FBC patients who were matched with the MBC patients for TNM stage, year of diagnosis, and age at diagnosis were simultaneously enrolled in the study. A second group comprising 18 MBC patients and their corresponding 36 matched postmenopausal FBC patients were also enrolled. The whole group and the postmenopausal groups were compared for five- and ten-year survivals. Results All the factors that could potentially affect prognosis were comparable among the groups except more FBC than MBC patients underwent endocrine therapy and a modified radical mastectomy. The 5- and 10-year survivals in the whole group were 81.6% and 60.3% for men and 90.7% and 73.5% for women （P=0.02）. The 5- and 10-year survival in the postmenopausal group was 82.5% and 100% for men and 66.0% and 85.9% for women （P=0.159）.Conclusions Chinese FBC patients had a better prognosis than Chinese MBC patients. However, MBC patients and their corresponding postmenopausal FBC patients had a similar prognosis.